OptiBerry May Halt Tumor Growth

OptiBerry May Halt Tumor Growth

BENICIA, Calif.InterHealth Nutraceuticals announced its OptiBerry,a standardized multiple berry extract, has demonstrated anti-angiogenicproperties in both in vitro and in vivo research. Angiogenesis is the processwhereby tumors develop a network of blood vessels; by shutting down thatprocess, researchers have hypothesized tumor growth can be halted. Researchconducted with OptiBerry at Ohio State University in Columbus, the University ofKuopio in Finland and Creighton University in Omaha, Neb., showed OptiBerrysignificantly inhibited angiogenesis, indicating its potential use againstcancer and inflammation.

The results of this study on OptiBerry, combined with the growing body ofresearch that points to anti-angiogenesis as a potentially powerful weapon inthe war against cancer, is truly exciting, said William Seroy, president andchief executive officer of InterHealth (www.interhealthusa.com).The anti-angiogenic benefits of OptiBerry, coupled with its potentantioxidant properties, make it an important natural supplement for todayshealth-conscious consumers.